LEWIS GEROGE SAL
No ORCID on file
· 25 papers in corpus
· active 2004-2007
Frequent coauthors
2007
Disclosed are selective estrogen receptor modulators containing a phenylsulfonyl group that are represented by formula (I) wherein the variables are as defined in the specification, a pharmaceutical acid addition salt thereof these compound…
2007
Disclosed are selective estrogen receptor modulators containing a phenylsulfonyl group that are represented by formula (I) wherein the variables are as defined in the specification, a pharmaceutical acid addition salt thereof these compound…
2007
Disclosed are selective estrogen receptor modulators containing a phenylsulfonyl group that are represented by formula (I) wherein the variables are as defined in the specification, a pharmaceutical acid addition salt thereof these compound…
2007
Disclosed are selective estrogen receptor modulators containing a phenylsulfonyl group that are represented by formula (I) wherein the variables are as defined in the specification, a pharmaceutical acid addition salt thereof these compound…
2007
Disclosed are selective estrogen receptor modulators containing a phenylsulfonyl group that are represented by formula (I) wherein the variables are as defined in the specification, a pharmaceutical acid addition salt thereof these compound…
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2005
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
2004
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.